Charles River Laboratories International (CRL) Stock Overview
Charles River Laboratories International, Inc. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
CRL Community Fair Values
Create NarrativeSee what 8 others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Charles River Laboratories International, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$174.90 |
| 52 Week High | US$228.88 |
| 52 Week Low | US$91.86 |
| Beta | 1.65 |
| 1 Month Change | -2.08% |
| 3 Month Change | -12.32% |
| 1 Year Change | 17.16% |
| 3 Year Change | -10.65% |
| 5 Year Change | -41.02% |
| Change since IPO | 695.00% |
Recent News & Updates
Recent updates
A Company Preparing for the Future: Charles River Laboratories
The Hidden Bottleneck in Drug Development: Why Charles River Acquired a Cambodian Primate Supplier On January 12, 2026, Charles River Laboratories announced that it had signed an agreement to acquire the assets of K.F. (Cambodia) Ltd., a major non-human primate (NHP) breeding and supply company. [$510M] At first glance, this transaction might appear to be a routine supply chain acquisition in the contract research organization (CRO) industry.Charles River Laboratories Q4 Review: Approaching A Bottom
Feb 18Is Now An Opportune Moment To Examine Charles River Laboratories International, Inc. (NYSE:CRL)?
Jan 10
Charles River Laboratories International, Inc.'s (NYSE:CRL) Low P/S No Reason For Excitement
Sep 09A Look At The Fair Value Of Charles River Laboratories International, Inc. (NYSE:CRL)
Aug 04Is Charles River Laboratories International (NYSE:CRL) Using Too Much Debt?
Jul 17There's No Escaping Charles River Laboratories International, Inc.'s (NYSE:CRL) Muted Revenues Despite A 25% Share Price Rise
May 24We Think Charles River Laboratories International, Inc.'s (NYSE:CRL) CEO Compensation Package Needs To Be Put Under A Microscope
May 14Charles River Faces Significant Regulatory And Macro Pressures
Apr 11Revenues Working Against Charles River Laboratories International, Inc.'s (NYSE:CRL) Share Price Following 30% Dive
Apr 09Charles River Laboratories: Retained Earnings, ROE, And Debt Management Will Shape Its Future Amid Weak Demand
Feb 01Charles River Labs: Near A Fundamental Trough, Growth Should Reignite Again
Jan 17Charles River Laboratories: Not The Right Time To Own At This Point In The Cycle
Nov 19
Cost Efficiency And Digital Strategy Propel Earnings Amidst Pharma Industry Challenges
Initiatives for cost efficiency and operational restructuring, including staff reductions, aim to boost net margins through significant annualized savings.Charles River Laboratories: Q2, Cost Structure Streamlining (Rating Upgrade)
Aug 10Shareholder Returns
| CRL | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 5.4% | 0.3% | -0.6% |
| 1Y | 17.2% | -1.3% | 16.0% |
Return vs Industry: CRL exceeded the US Life Sciences industry which returned -1.3% over the past year.
Return vs Market: CRL exceeded the US Market which returned 16% over the past year.
Price Volatility
| CRL volatility | |
|---|---|
| CRL Average Weekly Movement | 7.3% |
| Life Sciences Industry Average Movement | 8.4% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: CRL has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: CRL's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1947 | 19,000 | Jim Foster | www.criver.com |
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including genetically engineered models and services, insourcing solutions, and research animal diagnostic services; and engages in development and production of cell therapies.
Charles River Laboratories International, Inc. Fundamentals Summary
| CRL fundamental statistics | |
|---|---|
| Market cap | US$8.49b |
| Earnings (TTM) | -US$144.34m |
| Revenue (TTM) | US$4.02b |
Is CRL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CRL income statement (TTM) | |
|---|---|
| Revenue | US$4.02b |
| Cost of Revenue | US$2.61b |
| Gross Profit | US$1.40b |
| Other Expenses | US$1.55b |
| Earnings | -US$144.34m |
Last Reported Earnings
Dec 27, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.93 |
| Gross Margin | 34.98% |
| Net Profit Margin | -3.59% |
| Debt/Equity Ratio | 65.8% |
How did CRL perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/01 21:54 |
| End of Day Share Price | 2026/04/01 00:00 |
| Earnings | 2025/12/27 |
| Annual Earnings | 2025/12/27 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Charles River Laboratories International, Inc. is covered by 33 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Toung | Argus Research Company |
| Eric Coldwell | Baird |
| Douglas Tsao | Barclays |